Advertisement

Association of Antidiabetic Medications Targeting the Glucagon-Like Peptide 1 Pathway and Heart Failure Events in Patients With Diabetes

      Abstract

      Background

      Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors (GLP-1 agents) may be protective in heart failure (HF). We set out to determine whether GLP-1 agent use is associated with HF risk in diabetics.

      Methods and Results

      In this retrospective cohort study of members of a large health system, we identified >19,000 adult diabetics from January 1, 2000, to July 1, 2012. GLP-1 agent users were matched 1:2 to control subjects with the use of propensity matching based on age, race, sex, coronary disease, HF, diabetes duration, and number of antidiabetic medications. The association of GLP-1 agents with time to HF hospitalization was tested with multivariable Cox regression. All-cause hospitalization and mortality were secondary end points. We identified 1,426 users of GLP-1 agents and 2,798 control subjects. Both were similar except for angiotensin-converting enzyme inhibitors/angiotensin receptor blocker use, number of antidiabetic medications, and age. There were 199 hospitalizations, of which 128 were for HF, and 114 deaths. GLP-1 agents were associated with reduced risk of HF hospitalization (adjusted hazard ratio [aHR] 0.51, 95% confidence interval [CI] 0.34–0.77; P = .002), all-cause hospitalization (aHR 0.54, 95% CI 0.38–0.74; P = .001), and death (aHR 0.31, 95% CI 0.18–0.53; P = .001).

      Conclusions

      GLP-1 agents may reduce the risk of HF events in diabetics.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Roger V.L.
        • Go A.S.
        • Lloyd-Jones D.M.
        • Benjamin E.J.
        • Berry J.D.
        • Borden W.B.
        • et al.
        Executive summary: heart disease and stroke statistics–2012 update: a report from the American Heart Association.
        Circulation. 2012; 125: 188-197
        • Roger V.L.
        • Weston S.A.
        • Redfield M.M.
        • Hellermann-Homan J.P.
        • Killian J.
        • Yawn B.P.
        • et al.
        Trends in heart failure incidence and survival in a community-based population.
        JAMA. 2004; 292: 344-350
        • Kannel W.B.
        • Hjortland M.
        • Castelli W.P.
        Role of diabetes in congestive heart failure: the Framingham study.
        Am J Cardiol. 1974; 34: 29-34
        • Azevedo A.
        • Bettencourt P.
        • Almeida P.B.
        • Santos A.C.
        • Abreu-Lima C.
        • Hense H.W.
        • et al.
        Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities–cross-sectional study of the general population.
        BMC Cardiovasc Disord. 2007; 7: 17
        • Ingelsson E.
        • Arnlöv J.
        • Lind L.
        • Sundström J.
        Metabolic syndrome and risk for heart failure in middle-aged men.
        Heart. 2006; 92: 1409-1413
        • Domanski M.
        • Krause-Steinrauf H.
        • Deedwania P.
        • Follmann D.
        • Ghali J.K.
        • Gilbert E.
        • et al.
        The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.
        J Am Coll Cardiol. 2003; 42: 914-922
        • Dries D.L.
        • Sweitzer N.K.
        • Drazner M.H.
        • Stevenson L.W.
        • Gersh B.J.
        Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction.
        J Am Coll Cardiol. 2001; 38: 421-428
        • Guazzi M.
        • Brambilla R.
        • Pontone G.
        • Agostoni P.
        • Guazzi M.D.
        Effect of non-insulin-dependent diabetes mellitus on pulmonary function and exercise tolerance in chronic congestive heart failure.
        Am J Cardiol. 2002; 89: 191-197
        • Davidson M.H.
        Cardiovascular effects of glucagonlike peptide-1 agonists.
        Am J Cardiol. 2011; 108: 33B-41B
        • Liu Q.
        • Anderson C.
        • Broyde A.
        • Polizzi C.
        • Fernandez R.
        • Baron A.
        • et al.
        Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.
        Cardiovasc Diabetol. 2010; 9: 76
        • Nikolaidis L.A.
        • Mankad S.
        • Sokos G.G.
        • Miske G.
        • Shah A.
        • Elahi D.
        • et al.
        Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
        Circulation. 2004; 109: 962-965
        • Nathanson D.
        • Ullman B.
        • Löfström U.
        • Hedman A.
        • Frick M.
        • Sjöholm Å.
        • et al.
        Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.
        Diabetologia. 2012; 55: 926-935
        • Sokos G.G.
        • Nikolaidis L.A.
        • Mankad S.
        • Elahi D.
        • Shannon R.P.
        Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
        J Card Fail. 2006; 12: 694-699
        • Scirica B.M.
        • Bhatt D.L.
        • Braunwald E.
        • Steg P.G.
        • Davidson J.
        • Hirshberg B.
        • et al.
        Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
        N Engl J Med. 2013; 369: 1317-1326
        • White W.B.
        • Cannon C.P.
        • Heller S.R.
        • Nissen S.E.
        • Bergenstal R.M.
        • Bakris G.L.
        • et al.
        Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
        N Engl J Med. 2013; 369: 1327-1335
        • Alqaisi F.
        • Williams L.K.
        • Peterson E.L.
        • Lanfear D.E.
        Comparing methods for identifying patients with heart failure using electronic data sources.
        BMC Health Serv Res. 2009; 9: 237
        • Lee W.Y.
        • Capra A.M.
        • Jensvold N.G.
        • Gurwitz J.H.
        • Go A.S.
        Gender and risk of adverse outcomes in heart failure.
        Am J Cardiol. 2004; 94: 1147-1152
        • Wang T.S.
        • Hellkamp A.S.
        • Patel C.B.
        • Ezekowitz J.A.
        • Fonarow G.C.
        • Hernandez A.F.
        Representativeness of RELAX-AHF clinical trial population in acute heart failure.
        Circ Cardiovasc Qual Outcomes. 2014; 7: 259-268
        • Ban K.
        • Noyan-Ashraf M.H.
        • Hoefer J.
        • Bolz S.S.
        • Drucker D.J.
        • Husain M.
        Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor–dependent and –independent pathways.
        Circulation. 2008; 117: 2340-2350
        • Ravassa S.
        • Zudaire A.
        • Diez J.
        GLP-1 and cardioprotection: from bench to bedside.
        Cardiovasc Res. 2012; 94: 316-323
        • Nikolaidis L.A.
        • Elahi D.
        • Hentosz T.
        • Doverspike A.
        • Huerbin R.
        • Zourelias L.
        • et al.
        Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
        Circulation. 2004; 110: 955-961
        • Poornima I.
        • Brown S.B.
        • Bhashyam S.
        • Parikh P.
        • Bolukoglu H.
        • Shannon R.P.
        Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.
        Circ Heart Fail. 2008; 1: 153-160
        • Vyas A.K.
        • Yang K.C.
        • Woo D.
        • Tzekov A.
        • Kovacs A.
        • Jay P.Y.
        • et al.
        Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy.
        PLoS One. 2011; 6: e17178
        • Sokos G.G.
        • Bolukoglu H.
        • German J.
        • Hentosz T.
        • Magovern Jr., G.J.
        • Maher T.D.
        • et al.
        Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.
        Am J Cardiol. 2007; 100: 824-829
        • Read P.A.
        • Hoole S.P.
        • White P.A.
        • Khan F.Z.
        • O'Sullivan M.
        • West N.E.
        • et al.
        A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.
        Circ Cardiovasc Interv. 2011; 4: 266-272
        • Lonborg J.
        • Vejlstrup N.
        • Kelbaek H.
        • Botker H.E.
        • Kim W.Y.
        • Mathiasen A.B.
        • et al.
        Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
        Eur Heart J. 2012; 33: 1491-1499
        • Best J.H.
        • Hoogwerf B.J.
        • Herman W.H.
        • Pelletier E.M.
        • Smith D.B.
        • Wenten M.
        • et al.
        Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the Lifelink database.
        Diabetes Care. 2011; 34: 90-95
        • Johansen O.E.
        • Neubacher D.
        • von Eynatten M.
        • Patel S.
        • Woerle H.J.
        Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
        Cardiovasc Diabetol. 2012; 11: 3
        • Wu D.
        • Li L.
        • Liu C.
        Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
        Diabetes Obes Metab. 2014; 16: 30-37
        • Monami M.
        • Cremasco F.
        • Lamanna C.
        • Colombi C.
        • Desideri C.M.
        • Iacomelli I.
        • et al.
        Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.
        Exp Diabetes Res. 2011; 2011: 215764
        • Ratner R.
        • Han J.
        • Nicewarner D.
        • Yushmanova I.
        • Hoogwerf B.J.
        • Shen L.
        Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.
        Cardiovasc Diabetol. 2011; 10: 22
        • Sun F.
        • Yu K.
        • Wu S.
        • Zhang Y.
        • Yang Z.
        • Shi L.
        • et al.
        Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis.
        Diabetes Res Clin Pract. 2012; 98: 386-395
      1. ClinicalTrials.gov: A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/home. Accessed August 23, 2013.

        • Williams L.K.
        • Joseph C.L.
        • Peterson E.L.
        • Moon C.
        • Xi H.
        • Krajenta R.
        • et al.
        Race-ethnicity, crime, and other factors associated with adherence to inhaled corticosteroids.
        J Allergy Clin Immunol. 2007; 119: 168-175
        • Habib Z.A.
        • Havstad S.L.
        • Wells K.
        • Divine G.
        • Pladevall M.
        • Williams L.K.
        Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.
        J Clin Endocrinol Metab. 2010; 95: 592-600